Phase IV Study Of The Disease Characteristics, Treatment Patterns, Efficacy, Safety Management And PatientReported Outcomes Of Patients With Relapsed Or Refractory Large B- Cell Lymphoma Receiving Yescarta

Overview

About this study

The purpose of this study is describe AE management practices and outcomes of realworld, second-line Yescarta treatment in adults with LBCL. The following specific objectives have been developed to reach this research aim.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥18 years at time of providing informed consent

  • Eligible for, and planning to take Yescarta treatment for second line LBCL according to the labelled indication per the investigator discretion:

    • Yescarta is indicated for the treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy

  • Capable of providing informed consent and agree to collection of PROs

Exclusion Criteria:

  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the US Prescribing Information or to gentamicin (a possible trace residue)

  • Current participation in any interventional clinical trial at time of screening, or planned participation prior to Yescarta infusion

  • Prior treatment with CAR T therapy

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 02/02/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Urshila Durani, M.D., M.P.H.

Contact us for the latest status

Contact information:

Urshila Durani

5072845096

durani.urshila@mayo.edu

More information

Publications

Publications are currently not available